Agency says unproven claims about CBD products could lead consumers to delay medical care
WEDNESDAY, July 24, 2019 (HealthDay News) — A warning letter has been issued to Massachusetts-based Curaleaf Inc. for illegally selling unapproved cannabidiol (CBD) products online with unproven claims that the products treat cancer, Alzheimer disease, opioid withdrawal, pain, and other health problems, the U.S. Food and Drug Administration says.
Other than one prescription drug to treat rare, severe forms of epilepsy, the FDA has not approved any other CBD products, according to the agency.
It also noted that there is limited information for other CBD products being marketed to consumers and that they have not been evaluated for potential harm.
The FDA said that unproven claims about CBD products could lead consumers to delay important medical care, such as proper diagnosis and treatment.
Cannabis Use Linked to Earlier Age of Psychosis Onset 
Varenicline Can Cut Cannabis Use Among Men With Cannabis Use Disorder 
Study Compares Short-Term Use of Cannabinoid Products for Chronic Pain 
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists 
Air Pollution Tied to Higher Risk for Suicide 
Psychiatrists Only Agree 55 Percent of the Time on Diagnoses 
Youth Suicide Risk Linked to Community Firearm Violence 
